ETF Impact:
A quick look at the biotech ETFs movement in the last month will let you know exactly how concerned investors can get over regulation in pharmaceuticals. A simple shot across the bow from Hilary Clinton led to a rush of outflows from all the major ETFs in the space. Nasdaq Biotechnology (IBB) saw continued struggles on the back of poor earnings, bad press, and continued regulatory threats. Whether you see a buying opportunity or want no part – Canada is a great example of the real impact regulation can have on pharma profits – keeping a close eye on lawmakers is a good idea.
